Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases
作者:Emmanuel Bey、Sandrine Marchais-Oberwinkler、Patricia Kruchten、Martin Frotscher、Ruth Werth、Alexander Oster、Oztekin Algül、Alexander Neugebauer、Rolf W. Hartmann
DOI:10.1016/j.bmc.2008.04.073
日期:2008.6
The combination of a ligand- and a structure-based drug design approach led to the identification of bis(hydroxyphenyl) azoles as potential inhibitors of 17beta-HSD1. Different azoles and hydroxy substitution patterns were investigated. The compounds were evaluated for activity and selectivity with regard to 17beta-HSD2, ERalpha and ERbeta. The most potent compound is 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
17beta-羟基类固醇脱氢酶1(17beta-HSD1)催化将活性较弱的雌酮(E1)还原为最有效的雌激素17beta-雌二醇(E2)。E2通过激活雌激素受体(ER)刺激激素依赖性疾病的生长。17beta-HSD1通常在乳腺癌细胞中过表达。因此,它是治疗乳腺肿瘤的有吸引力的靶标。配体和基于结构的药物设计方法的结合导致了对双(羟苯基)唑类化合物作为17β-HSD1潜在抑制剂的鉴定。研究了不同的唑和羟基取代方式。评估了化合物相对于17beta-HSD2,ERalpha和ERbeta的活性和选择性。最有效的化合物是3- [5-(4-羟基苯基)-1,3-恶唑-2-基]苯酚(18,IC(50)= 0.31 microM),